<code id='FEB0CF5025'></code><style id='FEB0CF5025'></style>
    • <acronym id='FEB0CF5025'></acronym>
      <center id='FEB0CF5025'><center id='FEB0CF5025'><tfoot id='FEB0CF5025'></tfoot></center><abbr id='FEB0CF5025'><dir id='FEB0CF5025'><tfoot id='FEB0CF5025'></tfoot><noframes id='FEB0CF5025'>

    • <optgroup id='FEB0CF5025'><strike id='FEB0CF5025'><sup id='FEB0CF5025'></sup></strike><code id='FEB0CF5025'></code></optgroup>
        1. <b id='FEB0CF5025'><label id='FEB0CF5025'><select id='FEB0CF5025'><dt id='FEB0CF5025'><span id='FEB0CF5025'></span></dt></select></label></b><u id='FEB0CF5025'></u>
          <i id='FEB0CF5025'><strike id='FEB0CF5025'><tt id='FEB0CF5025'><pre id='FEB0CF5025'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:Wikipedia    Page View:4637
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In